Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma is asking stockholders to approve the potential issuance of up to 4,642,632 shares of common stock upon the exercise of pre-funded warrants and warrants tied to a May 2026 licensing transaction and related private placement. These securities relate to a global (ex‑Greater China) license for Ascendant-221 and an April 30, 2026 private placement that raised approximately $30 million in gross proceeds (about $28 million net) to advance the company’s clinical pipeline and fund working capital. The warrant shares equal about 142% of the 3,266,688 shares outstanding on April 30, 2026, so approval would significantly dilute existing holders if fully exercised. Stockholders are also being asked to approve a new 2026 Stock Incentive Plan with an initial 2,327,826-share pool plus rollover and evergreen increases to restore competitive equity incentives after recent financing-related dilution. The special meeting will be held virtually on June 1, 2026 for these votes and related matters.
Cue Biopharma reported first quarter 2026 results that show sharply higher collaboration revenue and a reduced net loss, alongside important strategic and financing steps. Revenue for the quarter rose to $5.7 million from $0.4 million a year earlier, mainly from its Boehringer Ingelheim collaboration. Research and development expenses declined to $6.9 million from $8.5 million, while general and administrative costs were stable at about $4.2 million. Net loss narrowed to $5.2 million from $12.3 million, and the company reported $16.4 million in cash and cash equivalents as of March 31, 2026.
After quarter-end, Cue Biopharma completed a $30 million private placement, yielding approximately $28 million in net proceeds, and received a $7.5 million preclinical milestone payment from Boehringer Ingelheim, strengthening near-term funding. Strategically, the company licensed CUE-221, a Phase 2 anti-IgE program for allergic disease, advanced CUE-401 toward Phase 1 for autoimmune conditions, and appointed Shao-Lee Lin, M.D., Ph.D., as President and CEO to lead its transition as a clinical-stage company.
Cue Biopharma, Inc. reported first-quarter 2026 results showing sharply higher collaboration revenue and a smaller loss, while still facing going concern risks. Collaboration revenue rose to $5.7 million from $0.4 million a year earlier, driven mainly by its partnership with Boehringer Ingelheim for B‑cell depletion programs.
The company’s net loss narrowed to $5.2 million, compared with $12.3 million in the prior-year quarter, helped by lower research and development spending. Cash, cash equivalents and restricted cash were $16.5 million as of March 31 2026, after using $10.9 million in operating cash during the quarter.
Management states that accumulated deficits, ongoing losses and limited cash raise substantial doubt about the ability to continue as a going concern, though it highlights an April 2026 1‑for‑30 reverse stock split, at‑the‑market share sales, and a $27.6 million May 2026 private placement of pre‑funded and common stock warrants as key capital-raising steps. The pipeline centers on lead antibody CUE‑221 in Phase 2 for allergic diseases and autoimmune candidate CUE‑401 progressing toward Phase 1.
Cue Biopharma, Inc. is soliciting proxies for a virtual Special Meeting of stockholders to be held on June 1, 2026 to vote on three proposals. Proposal 1 asks stockholders to approve issuance of up to 4,642,632 shares upon exercise of warrants issued in May 2026 related to a licensing transaction and private placement. Proposal 2 asks approval of the 2026 Stock Incentive Plan (requesting 2,327,826 new shares plus rollover and annual increases). Proposal 3 seeks authority to adjourn the meeting if further solicitation is needed.
Cue Biopharma, Inc. director and chief executive officer Shao-Lee Lin has filed an initial Form 3 statement of beneficial ownership with the SEC. The filing does not list any individual transactions or derivative positions, serving instead as a baseline disclosure of insider status at the company.
Cue Biopharma CEO Shao-Lee Lin reported equity awards on Common Stock. Lin received 327,537 shares of Common Stock and a stock option for 655,074 shares at an exercise price of $30.42 per share, vesting in 48 equal monthly installments beginning on April 30, 2026.
Cue Biopharma entered an exclusive license with Ascendant Health Sciences for Ascendant-221, a Phase 2 anti-IgE antibody, granting global rights outside Greater China. Cue will pay a $15 million upfront fee, up to $676.5 million in development, regulatory and commercial milestones, plus tiered royalties on net sales.
As partial consideration, Ascendant receives pre-funded warrants to buy 551,724 Cue shares at $0.001 per share and may be topped up to at least 7.5% beneficial ownership upon achieving specified milestones, subject to Nasdaq stockholder approvals and ownership caps. A related investor agreement adds lock-up, standstill and voting commitments.
Cue also agreed to a private placement of pre-funded warrants for up to 2,727,272 shares and accompanying warrants for up to 1,363,636 shares at $11.00, targeting roughly $30 million in gross proceeds to support the pipeline and Ascendant-221. The board adopted a 2026 Inducement Stock Incentive Plan covering 3,000,000 shares.
Dr. Shao-Lee Lin was appointed President and CEO with a $660,000 base salary, a target bonus of 55% of salary, an inducement option for 655,074 shares and 327,537 RSUs, with potential top-up equity to about 8.5% fully diluted ownership. Former interim CEO Lucinda Warren receives cash severance of $474,010.27, COBRA support and full vesting of time-based equity under a separation agreement.
Cue Biopharma entered an exclusive license with Ascendant Health Sciences for Ascendant-221, a Phase 2 anti-IgE antibody, granting global rights outside Greater China. Cue will pay a $15 million upfront fee, up to $676.5 million in development, regulatory and commercial milestones, plus tiered royalties on net sales.
As partial consideration, Ascendant receives pre-funded warrants to buy 551,724 Cue shares at $0.001 per share and may be topped up to at least 7.5% beneficial ownership upon achieving specified milestones, subject to Nasdaq stockholder approvals and ownership caps. A related investor agreement adds lock-up, standstill and voting commitments.
Cue also agreed to a private placement of pre-funded warrants for up to 2,727,272 shares and accompanying warrants for up to 1,363,636 shares at $11.00, targeting roughly $30 million in gross proceeds to support the pipeline and Ascendant-221. The board adopted a 2026 Inducement Stock Incentive Plan covering 3,000,000 shares.
Dr. Shao-Lee Lin was appointed President and CEO with a $660,000 base salary, a target bonus of 55% of salary, an inducement option for 655,074 shares and 327,537 RSUs, with potential top-up equity to about 8.5% fully diluted ownership. Former interim CEO Lucinda Warren receives cash severance of $474,010.27, COBRA support and full vesting of time-based equity under a separation agreement.
Cue Biopharma entered an exclusive license with Ascendant Health Sciences for Ascendant-221, a Phase 2 anti-IgE antibody, granting global rights outside Greater China. Cue will pay a $15 million upfront fee, up to $676.5 million in development, regulatory and commercial milestones, plus tiered royalties on net sales.
As partial consideration, Ascendant receives pre-funded warrants to buy 551,724 Cue shares at $0.001 per share and may be topped up to at least 7.5% beneficial ownership upon achieving specified milestones, subject to Nasdaq stockholder approvals and ownership caps. A related investor agreement adds lock-up, standstill and voting commitments.
Cue also agreed to a private placement of pre-funded warrants for up to 2,727,272 shares and accompanying warrants for up to 1,363,636 shares at $11.00, targeting roughly $30 million in gross proceeds to support the pipeline and Ascendant-221. The board adopted a 2026 Inducement Stock Incentive Plan covering 3,000,000 shares.
Dr. Shao-Lee Lin was appointed President and CEO with a $660,000 base salary, a target bonus of 55% of salary, an inducement option for 655,074 shares and 327,537 RSUs, with potential top-up equity to about 8.5% fully diluted ownership. Former interim CEO Lucinda Warren receives cash severance of $474,010.27, COBRA support and full vesting of time-based equity under a separation agreement.
Cue Biopharma, Inc. approved a 1-for-30 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026. The move is intended, among other things, to help the company meet the Nasdaq Capital Market’s minimum bid price requirement.
Every thirty issued and outstanding shares of common stock will be reclassified into one share, with stockholders receiving cash instead of fractional shares. The number of authorized shares and the $0.001 par value will remain unchanged. Outstanding options, warrants and equity plan share reserves will be proportionately adjusted, and post-split trading under the “CUE” symbol is expected to begin on April 24, 2026.
Cue Biopharma, Inc. held its 2026 annual meeting, where stockholders elected six directors and ratified the company’s independent auditor. A non-binding advisory proposal on executive compensation was also approved.
Stockholders further approved an amendment authorizing a reverse stock split of common stock at a ratio between 1-for-30 and 1-for-50, with the exact ratio and timing left to the Board’s sole discretion without further stockholder approval.
Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock. The award covers 200,000 stock options with an exercise price of $0.29 per share and an expiration date of April 8, 2036.
These options vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Sandercock holds 200,000 stock options directly, reflecting a routine compensation-related equity award rather than an open-market transaction.